CTCE9908 Inhibitor – CTCE 9908

CXCR4 antagonist; induces mitotic catastrophe in ovarian cancer cells. Displays additive cytotoxic effects when given with taxol (Cat. No. 1097). Enhances the efficacy of docetaxel (Cat. No. 4056) in a mouse model.

Kwong et al (2009) An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol.Cancer Ther. 8 1893 PMID:
Kwong et al (2009) An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol.Cancer Ther. 8 1893 PMID:
Hassan et al (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment,or doce. in a transgenic mouse model. Int.J.Cancer. 129 225 PMID:
Hassan et al (2011) CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment,or doce. in a transgenic mouse model. Int.J.Cancer. 129 225 PMID:
Faber et al (2007) The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J. Biomed. Biotechnol. 2007 26065 PMID:
Faber et al (2007) The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells. J. Biomed. Biotechnol. 2007 26065 PMID:

Small volumes of CTCE9908, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS5764046 is an inhibitor targeting CTCE9908. Also known as CTCE 9908.